Literature DB >> 1973751

Mechanisms involved in the development of adriamycin resistance in human leukemic cells.

S Kato1, H Ideguchi, K Muta, J Nishimura, H Nawata.   

Abstract

We have developed three adriamycin (ADR)-resistant K562 sublines with different degrees of resistance. These sublines show a decreased accumulation and an increased efflux of ADR in proportion to the degree of resistance. Two membrane proteins (mol. wt 170,000 and 230,000) reactive with monoclonal antibody against P-glycoprotein were highly expressed in both the K562/ADR200 and the K562/ADR500 subline. Less resistant K562/ADR80 cells contained only small amounts of mol. wt 230,000 protein. Thus, the level of P-glycoprotein expression was not proportionate to the degree of ADR efflux. Verapamil treatment could not completely reverse ADR resistance. No significant change of glutathione-s-transferase activity nor in the level of DNA topoisomerase II was detected in resistant sublines. In our sublines it seems that P-glycoprotein is one of the mechanisms for resistance, but additional mechanisms may be involved.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973751     DOI: 10.1016/0145-2126(90)90009-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

Review 1.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 2.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

3.  Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.

Authors:  J M Sargent; C J Williamson; C Yardley; C G Taylor; K Hellmann
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

4.  Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways.

Authors:  Xiaoyuan Jia; Yinsuo Zheng; Yanzi Guo; Kan Chen
Journal:  Mol Genet Genomic Med       Date:  2019-03-19       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.